Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN2350 phase 1/2 study in BAG3 mutation-associated dilated cardiomyopathy
2024-519674-40-00Phase 2Authorised
- Sponsor
- Alexion Pharmaceuticals
- Start
- Oct 2025
- Modality
- Gene Therapies
- Countries
- 5
01
Overview
Phase 2, open-label trial of ALXN2350 in dilated cardiomyopathy (DCM) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Safety and tolerability. Planned start Oct 2025; status: authorised.
02
Drugs
ALXN2350
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on 2024-519674-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519674-40-00.